McCallum Shannon (claussecond66)

portance of zonulin as the mediator of gluten obesogenic and inflammatory effects. Our data suggest that in the presence of gluten, zonulin release is associated with a reduction of REE and an increase of inflammatory markers that are not seen in zonulin low producers. Pre-clinical studies suggest that 164(n-3) in purified form or as a component of fish oil might induce platinum-based chemotherapy resistance. Our aim was to determine plasma total and free 164(n-3) before and during platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients supplemented with fish oil or provided standard care, and to explore relationships between plasma 164(n-3) levels and tumor response to treatment. In a retrospective, secondary data analysis of a prior clinical trial, plasma from patients with NSCLC (n=21) who underwent platinum-based chemotherapy and were assigned to 2.2g/day of eicosapentaenoic (EPA) plus 1.1g DHA/day as fish oil (FO; n=12) or received no intervention (standard care; SC; n=9). Plasma 164(n-3) was quantified as free and esterified (total) fatty acid using HPLC-MS/MS. Plasma 164(n-3) levels were evaluated over time in relation to fish oil supplementation and response to platinum-based therapy, and compared with a group of healthy subjects (REF; n=11). Plasma 164(n-3) was detected in all samples. The percentage change/day in plasma esterified (total) 164(n-3) was higher for FO versus SC group (2.7 versus-1.8%/d, U=20, p=0.02), but change in plasma free 164(n-3) was not different between FO and SC. Median plasma free and esterified 164(n-3) were similar between responders and non-responders to platinum-based chemotherapy. Donafenib order Total and free plasma 164(n-3) fatty acids were similar between NSCLC patients and REF (NSCLC vs REF total 164(n-3) 122.9 vs. 95.2nM and free 164(n-3) 23.9 vs. 27.6nM). This first of its kind study that evaluated plasma 164(n-3) in NSCLC patients showed that 164 (n-3) was elevated during FO supplementation, independent of fish oil supplementation or platinum-based chemotherapy. This first of its kind study that evaluated plasma 164(n-3) in NSCLC patients showed that 164 (n-3) was elevated during FO supplementation, independent of fish oil supplementation or platinum-based chemotherapy. The relation of some antioxidant nutrients with psychological disorders has been studied previously. The aim of this study was to examine the association between antioxidant vitamin intakes and the risk of depression, anxiety, and stress. This cross-sectional study was conducted on 263 Tehranian female adolescents. Dietary intakes of vitamin E, C, and β-Carotene were determined using a valid and reliable food-frequency questionnaire. Depression, anxiety, and stress scores were characterized by DASS-21 (Depression Anxiety Stress Score-21 items) questionnaire. The multivariable logistic regression models were used to determine the odds ratios (ORs) and 95% confidence intervals (95%CIs) of depression, anxiety, and stress across tertiles of antioxidant vitamin intakes. The mean±SD age of participants was 16.20±0.97 years. Also, the mean±SD depression, anxiety and stress scores of participants were 9.89±4.15, 8.43±4.39 and 14.00±6.45, respectively. In the fully adjusted model, subjects in the highest tertile of β-Carotene had a lower prevalence of depression (OR0.46, 95%CI0.23-0.95), anxiety (OR0.40, 95%CI0.20-0.81), and stress (OR0.35, 95%CI0.17-0.73) compared to the lowest tertile (P for trend<0.05). Moreover, individuals in the top tertile of vitamin E had a lower prevalence of stress, in comparison to the bottom tertile (OR0.34, 95% CI0.13-0.89), (P for trend<0.05). However, no significant associations were found between the intakes of vitamin E and C and other psychological disorders. In this study, higher intake of β-Carotene was associated with lower prevalence of depression, anxiety and stress. A